PixarBio (PixarBio) Price-to-Operating-Cash-Flow : (As of Jun. 19, 2024)

View and export this data going back to 2016. Start your Free Trial

What is PixarBio Price-to-Operating-Cash-Flow?

As of today (2024-06-19), PixarBio's share price is $1.0E-5. PixarBio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2016 was $0.00. Hence, PixarBio's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for PixarBio's Price-to-Operating-Cash-Flow or its related term are showing as below:

PXRB's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.955
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

PixarBio's Cash Flow from Operations per share for the three months ended in Sep. 2016 was $0.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2016 was $0.00.

PixarBio Price-to-Operating-Cash-Flow Historical Data

The historical data trend for PixarBio's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PixarBio Price-to-Operating-Cash-Flow Chart

PixarBio Annual Data

Trend

Dec14

Dec15

Price-to-Operating-Cash-Flow

PixarBio Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of PixarBio's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, PixarBio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PixarBio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PixarBio's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PixarBio's Price-to-Operating-Cash-Flow falls into.

PixarBio Price-to-Operating-Cash-Flow Calculation

PixarBio's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.0E-5	/	0
	=

PixarBio's Share Price of today is $1.0E-5.
PixarBio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

PixarBio Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of PixarBio's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

PixarBio (PixarBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PixarBio Corp (GREY:PXRB) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Boston Avenue, Suite 1875, Medford, MA, USA, 02155

Website

https://www.pixarbio.com

PixarBio Corp is a specialty pharmaceutical company focused on preclinical and clinical commercial development of therapeutic drug delivery systems for post-operative pain. The company's lead clinical candidate, NeuroRelease is a non-opioid / non-opiate preclinical stage product intended for the treatment of surgical pain, with planned future indications for chronic pain. NeuroRelease blocks nociceptive and neuropathic pain signals arising from temperature and pressure stimuli without affecting motor function, which is intended to allow for effective treatment without delaying post-surgical physical therapy.